18 F-FDG and 11 C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study

EJNMMI Research

Table 3 Difference in parameters with PFS > 4 months versus PFS ≤ 4 months

Modality	Parameters	PFS ≤ 4 months	PFS > 4 months	p value
CT	Sum of uni-dimensional measurements of target lesions (cm)	74.6 ± 42.8	69.2 ± 23.2	0.87
FDG	Highest SUV_max	12.8 ± 5.6	11.7 ± 4.4	0.95
	Sum of SUV_max	38.8 ± 41.6	28.6 ± 21.4	0.90
	MTV	138.0 ± 129.0	57.6 ± 43.5	0.19
	TLG	707.9 ± 701.7	292.3 ± 240.7	0.21
	SUL	10.0 ± 4.8	7.6 ± 3.3	0.28
	%Δhighest SUV_max	− 12.2 ± 37.8	− 12.0 ± 80.7	0.42
	%Δsum of SUV_max	− 19.2 ± 39.8	− 6.4 ± 85.1	0.79
	%ΔMTV	− 10.4 ± 59.4	− 29.1 ± 45.8	0.42
	%ΔTLG	− 10.9 ± 99.7	− 32.4 ± 79.0	0.33
	%ΔSUL	− 26.8 ± 47.5	− 34.4 ± 66.1	0.39
4DST	Highest SUV_max	6.8 ± 2.4	5.7 ± 1.7	0.11
	Sum of SUV_max	19.4 ± 17.8	22.8 ± 21.0	0.84
	MTV	127.7 ± 127.8	50.3 ± 29.2	0.06
	TLP	384.4 ± 371.0	158.4 ± 116.0	0.09
	%Δhighest SUV_max	11.9 ± 37.3	− 5.6 ± 47.9	0.33
	%Δsum of SUV_max	9.1 ± 49.5	− 18.6 ± 56.9	0.19
	%ΔMTV	− 18.9 ± 45.7	− 36.9 ± 52.4	0.33
	%ΔTLP	− 5.2 ± 77.9	− 32.9 ± 60.3	0.37

MTV metabolic tumor volume, TLG total lesion glycolysis, SUL standardized uptake value normalized by lean body mass, TLP total lesion proliferation